{
    "Trade/Device Name(s)": [
        "Xenta Drug Screen Cup",
        "Xenta Drug Screen Dipcard"
    ],
    "Submitter Information": "Xenta Biomedical Science Co., Ltd.",
    "510(k) Number": "K222955",
    "Predicate Device Reference 510(k) Number(s)": [
        "K153050"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DIO",
        "DJG",
        "LDJ",
        "DJC"
    ],
    "Summary Letter Date": "February 6, 2023",
    "Summary Letter Received Date": "September 27, 2022",
    "Submission Date": "September 27, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.3250",
        "21 CFR 862.3650",
        "21 CFR 862.3870",
        "21 CFR 862.3610"
    ],
    "Regulation Name(s)": [
        "Cocaine test system",
        "Morphine test system",
        "Cannabinoid test system",
        "Methamphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Marijuana (THC)",
        "Cocaine (COC)",
        "Methylenedioxymethamphetamine (MDMA)",
        "Methamphetamine (MET)",
        "Morphine (MOP)"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Lateral flow chromatographic immunoassay",
        "Competitive binding assay"
    ],
    "Methodologies": [
        "Immunochromatographic assay",
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Dipcard",
        "Cup"
    ],
    "Document Summary": "FDA 510(k) summary for Xenta Drug Screen Cup and Xenta Drug Screen Dipcard lateral flow immunoassays for qualitative drug detection in urine.",
    "Indications for Use Summary": "Qualitative detection of marijuana (THC), cocaine (COC), methylenedioxymethamphetamine (MDMA), methamphetamine (MET), and morphine (MOP) in human urine at specified cutoff concentrations for prescription use.",
    "fda_folder": "Toxicology"
}